We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-14.07%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.34B
AUM Growth
-$421M
Cap. Flow
+$11.7M
Cap. Flow %
0.5%
Top 10 Hldgs %
40.93%
Holding
221
New
9
Increased
52
Reduced
52
Closed
18

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$15.4M
2
MDT icon
Medtronic
MDT
+$13.3M
3
UNH icon
UnitedHealth
UNH
+$8.16M
4
ISRG icon
Intuitive Surgical
ISRG
+$7.42M
5
PFE icon
Pfizer
PFE
+$7.12M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$17M
2
AZN icon
AstraZeneca
AZN
+$11.3M
3
IDXX icon
Idexx Laboratories
IDXX
+$10.4M
4
VTRS icon
Viatris
VTRS
+$8.21M
5
OHI icon
Omega Healthcare
OHI
+$6.92M

Sector Composition

Rank Sector Weight
1 Healthcare 94.39%
2 Real Estate 2.48%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JNJ icon
1
Johnson & Johnson
JNJ
$617B
$133M 5.7%
1,032,628
+35,660
+4% +$4.97M
AMGN icon
2
Amgen
AMGN
$209B
$132M 5.65%
677,855
– –
BIIB icon
3
Biogen
BIIB
$30.7B
$119M 5.09%
394,902
+3,500
+0.9% +$1.12M
GILD icon
4
Gilead Sciences
GILD
$163B
$118M 5.06%
1,889,846
-52,471
-3% -$3.67M
UNH icon
5
UnitedHealth
UNH
$383B
$93.5M 4%
375,374
+30,888
+9% +$8.16M
CELG
6
DELISTED
Celgene Corp
CELG
$88.6M 3.79%
1,382,006
+69,656
+5% +$5.14M
ILMN icon
7
Illumina
ILMN
$31B
$78.7M 3.37%
269,726
+20,213
+8% +$6.26M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$122B
$70.6M 3.02%
426,248
+18,013
+4% +$3.12M
PFE icon
9
Pfizer
PFE
$142B
$66.2M 2.83%
1,598,700
+171,486
+12% +$7.12M
MRK icon
10
Merck
MRK
$321B
$56.4M 2.41%
773,537
+97,359
+14% +$6.87M
REGN icon
11
Regeneron Pharmaceuticals
REGN
$77.4B
$51M 2.18%
136,422
-9,815
-7% -$3.59M
ALXN
12
DELISTED
Alexion Pharmaceuticals
ALXN
$48.3M 2.07%
496,288
+57,872
+13% +$6.84M
ABBV icon
13
AbbVie
ABBV
$455B
$45.4M 1.94%
492,078
– –
MDT icon
14
Medtronic
MDT
$110B
$43.8M 1.87%
481,365
+141,926
+42% +$13.3M
TMO icon
15
Thermo Fisher Scientific
TMO
$214B
$42.9M 1.84%
191,895
+11,500
+6% +$2.7M
INCY icon
16
Incyte
INCY
$24.9B
$41M 1.76%
645,442
– –
VTRS icon
17
Viatris
VTRS
$20.7B
$38.5M 1.65%
1,403,728
-253,289
-15% -$8.21M
ELV icon
18
Elevance Health
ELV
$81.6B
$37.1M 1.59%
141,147
– –
BMY icon
19
Bristol-Myers Squibb
BMY
$132B
$33.9M 1.45%
652,966
+286,902
+78% +$15.4M
AGN
20
DELISTED
Allergan plc
AGN
$31.4M 1.34%
234,720
-14,116
-6% -$2.31M
CVS icon
21
CVS Health
CVS
$134B
$30.2M 1.29%
460,698
+59,597
+15% +$4.45M
ABT icon
22
Abbott
ABT
$183B
$28.3M 1.21%
391,719
– –
SYK icon
23
Stryker
SYK
$133B
$25.1M 1.08%
160,432
– –
LLY icon
24
Eli Lilly
LLY
$1.03T
$25M 1.07%
216,442
– –
NVS icon
25
Novartis
NVS
$301B
$25M 1.07%
325,556
-34,566
-10% -$2.69M
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Tekla Capital Management held 221 positions worth $2.34B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Tekla Capital Management's Q4 2018 filing shows 9 new, 52 increased, 52 reduced and 18 closed positions. Its largest new stake was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M. The largest sale was Aetna Inc, an estimated $17M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate and Financials.

  • Tekla Capital Management's largest Q4 2018 buy was Wellcare Health Plans, Inc.: 13,000 shares worth $3.07M.
  • Tekla Capital Management added most to Bristol-Myers Squibb in Q4 2018, an estimated $15.4M increase.
  • Tekla Capital Management's biggest Q4 2018 reduction was AstraZeneca, cutting an estimated $11.3M.
  • Tekla Capital Management fully exited Aetna Inc in Q4 2018, selling an estimated $17M.
  • Tekla Capital Management's ten largest holdings make up 41% of its $2.34B portfolio in Q4 2018.
  • Tekla Capital Management opened 9 new positions and closed 18 in Q4 2018.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.34B.

Based on Tekla Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.